中红普林医疗用品股份有限公司 章程 | | | 中红普林医疗用品股份有限公司 章程 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，建立中国特色现代 国有企业制度，规范公司的组织和行为，根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《中国共产党章程》（以下简称"《党章》"）和其他有关规定，制定本章程。 第二条 根据《党章》的规定，中红普林医疗用品股份有限公司（以下简称 "公司"）设立中国共产党的组织，开展党的活动。党组织发挥领导作用，把方 向、管大局、保落实。公司建立党的工作机构，配备足够数量的党务工作人员， 保障党组织的工作经费。 第三条 中红普林医疗用品股份有限公司系依照《公司法》和其他有关规定 成立的股份有限公司（上市、国有控股）。 公司经由唐山中红普林塑胶有限公司整体变更设立为股份有限公司，设立方 式为发起设立；在唐山市市场监督管理局注册登记，取得营业执照，统一社会信 用代码为 911302005661986189。 第四条 公司于 2021 年 3 月 9 日经中国证券监督管理委员会（以下简称"中 国证监会"）作出同意 ...

中红普林医疗用品股份有限公司 股东会议事规则 第一章 总则 第一条 为维护全体股东的合法权益，明确股东会职责和程序，保证股东会 依法行使职权，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司章程指引》《上市公司治理准则》《上市公司股东会规则》《上市公司独 立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规、规范 性文件和中红普林医疗用品股份有限公司（以下简称"公司"）章程的规定，制 定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、规范性文件及公司章程的相关 规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第四条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的 6 个月内举行。临时股东会不定期召开。 有下列情形之一的，公司在事实发生 ...

中红普林医疗用品股份有限公司 对外投资管理办法 第一章 总则 （二）必须符合公司的发展战略； （三）必须与公司规模相适应，不能影响公司主营业务发展； （四）必须坚持效益优先原则。 第四条 本办法适用于公司及公司全资子公司、控股子公司（以下简称"子公 司"）。 第二章 对外投资的审批权限 第五条 公司股东会、董事会、总经理为公司对外投资的决策机构，在各自的 权限范围内，对公司对外投资做出决策。 第一条 为规范公司对外投资行为，加强对外投资管理，控制对外投资风险， 保护投资者合法权益，根据《中华人民共和国公司法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等相关规定以及公司章程规定，结合公司实际情况，制定本办法。 第二条 本办法所称对外投资是指公司在境内外以现金、实物资产、无形资产 等作价出资，进行的各种形式的投资活动。 第三条 公司对外投资活动应当遵守以下原则： （一）必须符合国家有关法律、法规、规范性文件和产业政策的规定； 公司对外投资遵守企业国有资产监督管理相关法律法规、规章，遵守厦门市国 资委相关管理制度，公司对外投资额度、投向等方面达 ...

中红医疗公告，2025年上半年营业收入12.38亿元，同比增长7.76%。净利润574.29万元，同比下降 82.35%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2025, representing a 15% increase compared to the same period in 2024[1]. - The net profit attributable to shareholders for the first half of 2025 was RMB 80 million, up 20% year-over-year[1]. - The company's operating revenue for the reporting period was ¥1,237,534,880.54, representing a 7.76% increase compared to ¥1,148,451,821.02 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 82.35% to ¥5,742,934.20 from ¥32,529,868.67 year-on-year[19]. - Basic earnings per share decreased by 82.37% to ¥0.0134 from ¥0.0836 in the same period last year[19]. - The weighted average return on net assets fell to 0.10%, down from 0.56% year-on-year[19]. - The net cash flow from operating activities improved by 62.01%, reaching -¥32,256,511.24 compared to -¥84,900,776.67 in the previous year[19]. - The company reported a significant decrease in income tax expenses by 62.54%, amounting to ¥1,984,183.20 compared to ¥5,297,347.46 in the previous year[84]. Market Expansion and Product Development - User data indicates a growth in active users by 25%, reaching a total of 1.5 million users by June 30, 2025[1]. - The company plans to launch two new product lines in Q4 2025, focusing on advanced medical gloves and protective equipment[1]. - Future outlook includes an estimated revenue growth of 10-15% for the full year 2025, driven by market expansion and new product introductions[1]. - The company is actively expanding in the medical device industry, establishing four major divisions: health protection, safe infusion, innovation incubation, and international development[28]. - The company is exploring potential acquisitions to strengthen its market position and expand its product portfolio[1]. - The company is focusing on product development, process optimization, and quality improvement to strengthen its position as a leading enterprise in the industry[40]. - The company is focusing on high-end product development, particularly in precision infusion devices, to maintain market competitiveness[61]. - The company is committed to enhancing its product portfolio with innovative solutions that meet the evolving needs of healthcare providers and patients[71]. Research and Development - Research and development expenses increased by 30% in the first half of 2025, reflecting the company's commitment to innovation[1]. - The company holds a total of 235 patents, including 65 invention patents, 128 utility model patents, and 42 design patents[68]. - The company has made breakthroughs in new materials, processes, and equipment automation through R&D and production integration[68]. - Significant R&D resources have been invested in developing high-end reproductive health products under the "Zhonghong" brand[68]. - The R&D team at the subsidiary Maiderina has extensive industry experience, further enhancing the company's overall R&D strength[68]. Strategic Partnerships and Acquisitions - The company has initiated a strategic partnership with a leading healthcare provider to enhance distribution channels and market reach[1]. - The company has successfully acquired 75% of SEA3 in Southeast Asia, enhancing its production capacity for protective gloves and implementing an international strategy to adapt to changing global policies[63]. - The company acquired a 90% stake in Kelong Medical, expanding the product line to include infusion devices, enhancing operational synergy[125]. - The company acquired a 70% stake in Hengbao Health, which produces latex medical gloves and condoms, leveraging the Medispo brand's global presence in over 50 countries[126]. Financial Management and Compliance - The company has a strong cash flow position with a low debt-to-asset ratio, providing a solid foundation for future investments and acquisitions[79]. - The company has established five dedicated accounts for the management of raised funds, ensuring strict compliance with regulatory agreements[107]. - The company has implemented a strict approval process for the use of raised funds to ensure they are used for their intended purposes[106]. - The company has a robust compliance management system, adhering to regulations set by the China Securities Regulatory Commission and stock exchanges[75]. - The company is committed to compliance with the Shenzhen Stock Exchange's disclosure requirements for medical device businesses[68]. Risks and Challenges - The company faces risks related to international market fluctuations and regulatory changes, which may impact future performance[1]. - The company is facing risks from international market fluctuations, particularly in exports to Europe, Japan, and Australia, which could impact operations[127]. - The company reported a significant increase in production costs due to raw material and energy price fluctuations, which could affect profitability[132]. - The company is exploring mergers and acquisitions to strengthen its market position and diversify its product offerings[128]. Corporate Governance and Shareholder Information - The company is controlled by the Xiamen State-owned Assets Supervision and Administration Commission, ensuring strong governance and compliance[75]. - The company has maintained a stable financial position with no non-operating fund occupation by controlling shareholders or related parties[149]. - The company reported a total of 20,153 shareholders at the end of the reporting period[189]. - The largest shareholder, Zhonghong Pulin Group, holds 45.01% of the shares, with a total of 1,930,500 shares added during the reporting period[190]. - The company distributed cash dividends of 2.5 yuan per 10 shares, totaling 97,142,899.50 yuan, and increased its total share capital by 38,857,159 shares[176].

Core Viewpoint - 中红医疗's stock experienced a decline of 1.72% on August 26, with a trading volume of 144 million yuan, indicating a potential market reaction to recent financial data and trading activities [1] Financing Summary - On August 26, 中红医疗 had a financing buy-in amount of 19.84 million yuan and a financing repayment of 18.52 million yuan, resulting in a net financing buy of 1.32 million yuan [1] - The total financing and securities balance for 中红医疗 reached 147 million yuan, accounting for 2.14% of its market capitalization, which is above the 90th percentile of the past year [1] - The company had no short selling activity on August 26, with a short selling balance of 0.0772 million yuan and a short selling volume of 4,820 shares, also above the 90th percentile of the past year [1] Business Performance - As of March 31, 中红医疗 reported a total of 20,100 shareholders, a decrease of 8.24%, while the average circulating shares per person increased by 8.98% to 17,807 shares [2] - For the first quarter of 2025, 中红医疗 achieved a revenue of 629 million yuan, representing a year-on-year growth of 15.45%, and a net profit attributable to shareholders of 18.92 million yuan, which is a significant increase of 1,369.95% year-on-year [2] Dividend Information - Since its A-share listing, 中红医疗 has distributed a total of 1.251 billion yuan in dividends, with 501 million yuan distributed over the past three years [3] Shareholding Structure - As of March 31, 2025, 中红医疗's fifth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 993,400 shares, which is a decrease of 1.7963 million shares compared to the previous period [3]

Core Viewpoint - Zhonghong Medical (300981) experienced a decline in stock price, closing at 16.01 yuan on August 26, 2025, down 1.72% with a trading volume of 90,000 hands and a turnover of 144 million yuan [1] Group 1: Stock Performance and Trading Data - On August 26, 2025, the net outflow of main funds was 10.797 million yuan, accounting for 7.47% of the total turnover, while retail investors saw a net inflow of 12.0068 million yuan, representing 8.31% of the total turnover [1] - The stock's performance over the past five days shows fluctuations, with a peak closing price of 16.29 yuan on August 25, 2025, and a significant drop of 4.01% on August 20, 2025 [2] Group 2: Financial Metrics and Industry Comparison - Zhonghong Medical's total market value is 6.866 billion yuan, which is below the industry average of 12.328 billion yuan, ranking 53 out of 123 in the medical device industry [3] - The company reported a net profit of 18.9211 million yuan for Q1 2025, a significant increase of 1369.95% year-on-year, with a gross margin of 13.36%, which is considerably lower than the industry average of 51.29% [3] - The company's return on equity (ROE) stands at 0.35%, compared to the industry average of 1.83%, indicating a lower profitability relative to peers [3]

Core Insights - The article reveals the new heavy stock positions of pension funds in the second quarter, highlighting the significant investments in 29 stocks that reflect the strategic trends in the industry, particularly in high-end manufacturing and technology [1] Fund Movement - Pension funds have invested in 11 stocks with a market value exceeding 100 million, with Satellite Chemical alone receiving an investment of 346 million [3] - The overlap rate between pension and social security funds is 57%, indicating a strong consensus on 29 stocks, which is rare in the past five years [3] Key Investment Themes 1. **Domestic Substitution in Deep Water**: - Shengyi Electronics was heavily purchased with 273 million, showing a 452% increase in net profit in the first half of the year. Its expansion in high-layer PCB boards is crucial for NVIDIA's H100 servers, especially as the U.S. tightens AI chip exports [3] 2. **Breakthroughs in Technology Blockades**: - Satellite Chemical invested 773 million in R&D for high-end new materials, aiming to break Dow Chemical's monopoly with POE photovoltaic adhesive raw materials and targeting NVIDIA's GPU liquid cooling solutions [3] 3. **True Leaders in Consumption Recovery**: - Hongfa Technology, despite a modest 14% growth, secured 80% of orders for automotive relays from Tesla and BYD, benefiting from the resurgence of Huawei smartphones with a 40% increase in quarterly shipments [4] Investment Strategy Insights - Pension funds typically hold positions for over three years, with Changhai Co. holding for 21 quarters. New investments in Huafeng Aluminum and Luxi Chemical are considered strong cyclical stocks, indicating potential volatility [5] - Key details for mid-to-long-term investment include: - **Shareholder List Importance**: Satellite Chemical's major shareholders include both pension funds and the Norwegian sovereign fund, indicating strong backing [6] - **R&D Investment as a Benchmark**: The average R&D expense ratio for heavily invested stocks is 6.2%, significantly higher than the A-share average of 3.1%, with Shengyi Electronics' R&D expenses increasing by 210% leading to a 452% profit growth [6] - **Caution Against Isolated Stocks**: The strength of institutional backing is crucial for resilience against market downturns, as seen with Spring Wind Power and Cambridge Technology [6]

Group 1 - The stock price of Zhonghong Medical is reported at 15.95 yuan, down 0.01 yuan from the previous trading day, with a decline of 0.06% [1] - The opening price for the day was 16.10 yuan, reaching a high of 16.15 yuan and a low of 15.75 yuan, with a trading volume of 98,899 hands and a transaction amount of 1.57 billion yuan [1] - Zhonghong Medical operates in the medical device sector, focusing on the research, production, and sales of medical polymer products, including disposable sterile syringes and infusion devices [1] Group 2 - The subsidiary Shenzhen Maide Ruina recently obtained a medical device registration certificate for infusion pumps from the Guangdong Provincial Drug Administration [1] - The infusion pump is designed to be used with infusion lines for intravenous medication delivery, excluding analgesics, chemotherapy drugs, and insulin, and can also be used with enteral nutrition infusion lines for adjustable nutrient delivery [1] Group 3 - On August 22, the net outflow of main funds was 23.52 million yuan, accounting for 0.38% of the circulating market value [1] - Over the past five days, the cumulative net outflow of main funds reached 59.99 million yuan, representing 0.96% of the circulating market value [1]

Core Viewpoint - Zhonghong Medical (300981) experienced a slight decline in stock price, closing at 15.95 yuan on August 22, 2025, with a trading volume of 9.89 million shares and a total transaction amount of 1.57 billion yuan [1] Group 1: Financial Performance - The company reported a main revenue of 629 million yuan for Q1 2025, representing a year-on-year increase of 15.45% [3] - The net profit attributable to shareholders was 18.92 million yuan, showing a significant year-on-year increase of 1369.95% [3] - The net profit after deducting non-recurring gains and losses was 11.37 million yuan, up 164.39% year-on-year [3] - The company's debt ratio stands at 24.09% [3] Group 2: Market Position and Ratios - Zhonghong Medical's total market value is 6.84 billion yuan, compared to the industry average of 12.243 billion yuan, ranking 53 out of 123 in the industry [3] - The company's net assets are 5.64 billion yuan, above the industry average of 3.893 billion yuan, ranking 23 out of 123 [3] - The price-to-earnings ratio (P/E) is 90.38, higher than the industry average of 77.99, ranking 73 out of 123 [3] - The price-to-book ratio (P/B) is 1.27, significantly lower than the industry average of 4.01, ranking 13 out of 123 [3] - The gross margin is 13.36%, while the industry average is 51.31%, ranking 121 out of 123 [3] - The net margin is 3.08%, compared to the industry average of 10.85%, ranking 94 out of 123 [3] - The return on equity (ROE) is 0.35%, lower than the industry average of 1.65%, ranking 94 out of 123 [3] Group 3: Capital Flow Analysis - On August 22, 2025, the main funds experienced a net outflow of 23.52 million yuan, accounting for 14.95% of the total transaction amount [1][2] - Retail investors saw a net inflow of 24.21 million yuan, representing 15.38% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuating capital flows, with notable outflows from main and speculative funds on several days [2]